Read Bill McGivney's editorial comment in OBR regarding an executive order aiming to address high prescription drug prices:...

October 2018: Collaboration with McGivney Global Advisors results in NCCN Preferred positioning for our client's product In today's...

By Jon Larsen, JD, MPP, McGA Policy Consultant In August 2018, the Centers for Medicare and Medicaid Services (CMS) rescinded 2012...

Join Niesha Griffith, RPh of McGivney Global Advisors for an online discussion on Tuesday, July 17th at 11:30AM ET with Julie...

Blockchain is a buzzword in tech, but does it hold more than hype for the pharma and biotech industry? Explore biopharma business use...

Could Trump's new drug plan give new life to the Competitive Acquisition Program? Tuesday, May 29th at NOON ET Please join McGivney...

McGivney Global Advisors is pleased to partner with the Lynx Group to recognize the contributions that individuals under the age of 40...

This March 2018, the Medicare Payment Advisory Commission (MedPAC), an independent congressional agency tasked with advising Congress...

Read Original Article: Alphabet-backed Flatiron Health is being acquired by Roche Response from Bill McGivney: I do not what they call...

The NCCN Guidelines and Drug/Biologics Compendium have justifiably earned the Preferred position as the most influential resources in...

Prior to the ICER meeting to review evidence and vote on cost-effectiveness ratings for NSCLC treatments, five prominent oncologists...

I have extensive experience in “real world” policy-setting and decision-making and I am puzzled about the motivations regarding the...

McGivney Global Advisors publishes quarterly reports  assessing the changes and impact of Oncology Value Metrics, including NCCN Evidence...

Will a spate of recent lawsuits shift the balance of power in the health care industry? While no companies in the health care industry...

With new developments in immuno-oncology and targeted therapies, there has never been a more hopeful time for people fighting cancer....

A McGivney Global Advisors op-ed on Oncology Value Metrics and ICER was referenced by the Biotechnology Industry Organization, quoting...

(AJMC) Apr 7, 2016 - Drug developer Amgen is questioning the assessment of its multiple myeloma treatments at the hands of the Institute...

Medicare announced in February 2016 that it is going to create a “demo project” that can randomize how cancer doctors are paid depending...